2011 - IPITA - Prague


Parallel session 2 – Open oral presentations Topic: Results of clinical autologous and allogeneic islet transplantation

2.5 - Islets after Kidney Transplantation in the GRAGIL network: impact of the number of infusions

Presenter: S., Borot, Geneva, Switzerland
Authors: S. Borot, N. Niclauss, A. Wojtusciszyn, C. Brault, Y. Müller, L. Giovannoni, G. Parnaud, R. Meier, L. Badet, F. Bayle, L. Kessler, E. Morelon, A. Penfornis, C. Thivolet, C. Toso, P. Morel, D. Bosco, C. Colin, P.Y. Benhamou, T. Berney



Islets after Kidney Transplantation in the GRAGIL network: impact of the number of infusions

S. Borot1, N. Niclauss1, A. Wojtusciszyn2, C. Brault3, Y. Müller1, L. Giovannoni1, G. Parnaud1, R. Meier1, L. Badet4, F. Bayle5, L. Kessler6, E. Morelon7, A. Penfornis8, C. Thivolet9, C. Toso1, P. Morel1, D. Bosco1, C. Colin3, P.Y. Benhamou10, T. Berney1
1 Geneva University Hospitals, Islet Isolation and Transplantation Center, GENEVA 14, Switzerland; 2 Diabetology, Montpellier University Hospitals, Montpellier, France; 3 Pôle Information Médicale Evaluation Recherche, Hospices Civils de Lyon, Lyon, France; 4 Urology and Transplantation surgery, Hospices Civils de Lyon, Lyon, France; 5 Nephrology, Grenoble University Hospital, Grenoble, France
6 Diabetology, Strasbourg University Hospitals, Strasbourg, France; 7 Nephrology, Hospices Civils de Lyon, Lyon, France; 8 Diabetology, Besançon University Hospital, Besançon, France; 9 Diabetology, Hospices Civils de Lyon, Lyon, France; 10 Diabetology, Grenoble University Hospitals, Grenoble, France

Background: Insulin independence after islet transplantation is generally achieved after multiple islet infusions. However, single infusions would allow increasing the number of islet transplant recipients. The aim of this study was to evaluate the results of IAK transplantation in type 1 diabetic patients according to the number of islet infusions.

Methods: Islets were isolated at the University of Geneva and shipped and transplanted between 2004 and 2010 into French patients from the Swiss-French GRAGIL network, on the “Edmonton” immunosuppression protocol.

Results: Nineteen patients were transplanted with 33 preparations isolated from 36 donors. Fifteen patients reached 24 months follow-up after the first islet infusion: 8 subjects were single graft recipients (Group 1) and 7 were double graft recipients (Group 2). Single graft recipients received 5,312 IEQ/kg (5,186-6,388) vs 10,564 (10,054-11,375) for double graft recipients. Insulin-independence was achieved in 5/8 Group 1 subjects vs 5/7 in Group 2 subjects. Insulin-independence duration was 4.7 months (3.1-15.2) in Group 1 vs 19 months (9.6-20.8) in Group 2. At 24 months post-transplant, insulin doses were reduced by 58% in Group 1 (31-80) vs 97% (60-100) in Group 2, HbA1c was 6.5% (5.9-6.8) in Group 1 vs 6.2% (5.9-6.3) in Group 2, and basal C-peptide was 0.9 ng/mL (0.4-1.4) in Group 1 vs 1.8 (1.2;2.4) in Group 2.

Conclusions: One infusion achieves good glycemic control and sometimes insulin-independence. However, patients with 2 infusions remain insulin-free longer, and have lower HbA1c and better graft function 24 months after the first transplant.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi